<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950989</url>
  </required_header>
  <id_info>
    <org_study_id>20090061</org_study_id>
    <nct_id>NCT00950989</nct_id>
  </id_info>
  <brief_title>AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled study in subjects with RA who have an inadequate
      response to methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 50 response at week 12.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the following: The proportion of subjects with an ACR 20 and 70 at week 12 and Disease Activity Score 28 joint (DAS28) at week 12.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the short term safety profile of AMG 827 in subjects with rheumatoid arthritis (RA)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) of AMG 827 in subjects with Rheumatoid Arthritis (RA)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>AMG 827 210 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>210 mg AMG 827</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 827 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>140 mg AMG 827</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 827 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70mg AMG 827</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 827 70 mg</intervention_name>
    <description>70 mg AMG 827 SC</description>
    <arm_group_label>AMG 827 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 827 140 mg</intervention_name>
    <description>140 mg AMG 827 SC</description>
    <arm_group_label>AMG 827 140 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 827 210 mg</intervention_name>
    <description>210 mg AMG 827 SC</description>
    <arm_group_label>AMG 827 210 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stable weekly dose of methotrexate</intervention_name>
    <description>Methotrexate</description>
    <arm_group_label>AMG 827 210 mg</arm_group_label>
    <arm_group_label>AMG 827 140 mg</arm_group_label>
    <arm_group_label>AMG 827 70 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active RA for least 6 months

          -  Current RA defined as ≥ 6 swollen joints (out of 66 joints examined) and ≥ 8
             tender/painful joints (out of 68 joints examined) at screening and baseline (swollen
             and tender/painful joint count must not include distal interphalangeal joints) and at
             least 1 of the following at screening: Erythrocyte sedimentation rate ≥ 28 mm or
             C-reactive protein &gt; 15 mg/L

          -  At least 1 of the following at screening: Rheumatoid factor positive or Anti-cyclic
             citrullinated peptide antibody positive

          -  Currently taking methotrexate for ≥ 12 weeks and on a stable dose of methotrexate at
             15 to 25 mg weekly for ≥ 4 weeks at day -1.

        Exclusion Criteria:

          -  Prosthetic joint infection within 5 years of screening or native joint infection
             within 1 year of screening

          -  Class IV RA

          -  Felty's syndrome

          -  Presence of serious infection

          -  Significant concurrent medical conditions

          -  Pregnant or breast feeding

          -  Significant Laboratory abnormalities

          -  Any DMARD other than methotrexate within 28 days

          -  Leflunomide or live vaccines within 3 months

          -  Previous use of any experimental or commercially available biologic DMARD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol. 2015 Jun;42(6):912-9. doi: 10.3899/jrheum.141271. Epub 2015 Apr 15.</citation>
    <PMID>25877498</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <disposition_first_submitted>November 14, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 14, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 6, 2013</disposition_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Arthritis, Rheumatoid</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

